About this Research Topic
Lymphoid innate populations substantially contribute to anti-tumor immunity in solid tumors and
hematological malignancies. Pre-existing innate response as well as innate immune reactions upon
treatment with chemotherapy, targeted therapy, radiotherapy or cell therapy, are cornerstones of
the obtainment and maintenance of long-term complete remissions. However, several facets of
these alterations as well as the mechanisms involved in the attenuation of innate responses remain
poorly described. A better description of these alterations is crucial to better appreciate the
functional and the phenotypical consequences of direct and indirect interactions with tumor cells,
some of which being a potential source of prognostic biomarkers. On the other hand, the elucidation
of these mechanisms will eventually provide a rationale basis for effective manipulation of these
immune populations for therapeutic applications. Taking into account the clear prognostic value
often associated with perturbation of the homeostasis of innate immunity, therapeutic strategies
aiming at restoring innate anti-tumor functions are expected to impact clinical outcome of cancer
patients.
In this context, the main aim of this Research Topic is to cover recent advances of basic research on
lymphoid innate immune responses, to potential applications through translational studies in
hematology that bridge the gap between fundamental knowledge and potential clinical applications.
We welcome the submission of Original Research, Systematic Review, Methods, Review, Mini-
Review, Clinical Trial, and Perspective articles including, preferentially covering but not limited to the
following topics:
- Description of novel alterations of the lymphoid innate immune compartment in solid tumors
and hematological malignancies
- Identification of mechanisms leading to impairment of lymphoid innate immune responses
- Immunotherapy of malignant diseases based on manipulation of innate lymphoid
populations using cytokines, monoclonal antibodies or bispecific antibodies
- Autologous or allogeneic cellular therapy of malignant diseases using innate immune
lymphoid populations
- Methods for ex vivo expansion and activation of autologous or allogeneic anti-tumor
lymphoid cells for cell therapy, including, but not restricted to, NK cells, NKT cells, and γδ T
cells
- Innate and innate-like cells as platforms for CAR development
- Biomarkers based on innate immune parameters associated with prognosis or clinical
response to chemotherapy, targeted therapy or immunotherapy.
hematological malignancies. Pre-existing innate response as well as innate immune reactions upon
treatment with chemotherapy, targeted therapy, radiotherapy or cell therapy, are cornerstones of
the obtainment and maintenance of long-term complete remissions. However, several facets of
these alterations as well as the mechanisms involved in the attenuation of innate responses remain
poorly described. A better description of these alterations is crucial to better appreciate the
functional and the phenotypical consequences of direct and indirect interactions with tumor cells,
some of which being a potential source of prognostic biomarkers. On the other hand, the elucidation
of these mechanisms will eventually provide a rationale basis for effective manipulation of these
immune populations for therapeutic applications. Taking into account the clear prognostic value
often associated with perturbation of the homeostasis of innate immunity, therapeutic strategies
aiming at restoring innate anti-tumor functions are expected to impact clinical outcome of cancer
patients.
In this context, the main aim of this Research Topic is to cover recent advances of basic research on
lymphoid innate immune responses, to potential applications through translational studies in
hematology that bridge the gap between fundamental knowledge and potential clinical applications.
We welcome the submission of Original Research, Systematic Review, Methods, Review, Mini-
Review, Clinical Trial, and Perspective articles including, preferentially covering but not limited to the
following topics:
- Description of novel alterations of the lymphoid innate immune compartment in solid tumors
and hematological malignancies
- Identification of mechanisms leading to impairment of lymphoid innate immune responses
- Immunotherapy of malignant diseases based on manipulation of innate lymphoid
populations using cytokines, monoclonal antibodies or bispecific antibodies
- Autologous or allogeneic cellular therapy of malignant diseases using innate immune
lymphoid populations
- Methods for ex vivo expansion and activation of autologous or allogeneic anti-tumor
lymphoid cells for cell therapy, including, but not restricted to, NK cells, NKT cells, and γδ T
cells
- Innate and innate-like cells as platforms for CAR development
- Biomarkers based on innate immune parameters associated with prognosis or clinical
response to chemotherapy, targeted therapy or immunotherapy.
Keywords: innate immunity, NK cells, ILC, innate T lymphocytes, MAIT cells, NKT cells, γδ T cells.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
